Elekta : Year-end report May-April 2019/20

Performing in a difficult time

In summarizing the full year we had a modest growth due to challenges linked to Covid-19 in our most important fourth quarter.
I am very proud of how Elekta has handled the pandemic effects, in particular supporting our customers, strengthening our solution portfolio and delivering profit. We are in a good position for the future based on our innovative solutions and a strong backlog enhanced by a record order after the year closed. With this order we exceeded our Unity order target while increasing our U.S. market position.

Richard Hausmann
President and CEO

Fourth quarter

·
Covid-19 had a large effect on the fourth quarter

·
Gross order intake amounted to SEK 5,032 M (5,401), corresponding to a 10 percent decrease in order intake in constant currency

·
Net sales were SEK 4,008 M (4,086), corresponding to a 6 percent decrease in constant currency

·
Gross margin amounted to 42.6 (45.2) percent

·
EBITA decreased by 10 percent to SEK 886 M (985), corresponding to an EBITA margin of 22.1 percent (24.1)

·
Earnings per share was SEK 1.07 (1.40) before/after dilution

·
Cash flow after continuous investments was SEK 1,026 M (1,359)

·
4 Elekta Unity orders booked in the quarter

 

Full year

·
Gross order intake amounted to SEK 17,735 M (16,796), corresponding to a 1 percent growth in constant currency

·
Net sales were SEK 14,601 M (13,555), corresponding to a 3 percent growth in constant currency

·
Gross margin amounted to 42.0 (41.9) percent

·
EBITA amounted to SEK 2,521 M (2,477), corresponding to an EBITA margin of 17.3 percent (18.3)

·
Earnings per share was SEK 2.84 (3.14) before/after dilution

·
Cash flow after continuous investments was SEK 252 M (962)

· 24 Elekta Unity orders booked in the period
 

Significant events after the quarter

·
GenesisCare ordered several Elekta linear accelerators at a value of around USD 200 million (approx. SEK 2 bn) over the next five years, of which 11 are Elekta Unity MR-Linac systems, as GenesisCare enters the U.S. market.

· Acquisition of Kaiku Health strengthens Elekta Digital offering with personalized remote digital health interventions.

[image]

[1] After continuous investments
[2 ]Before / after dilution
[3] Compared to last fiscal year based on constant currency
 

Dividend for fiscal year 2019/20 

·
The Board of Directors will make the decision of the proposed dividend on July 10, 2020. 

# # #

For further information, please contact:
Cecilia Ketels, Head of Investor Relations
Tel: [phone], e-mail: [e-mail]
Time zone: CET: Central European Time

Gustaf Salford, CFO 
Tel: [phone], e-mail: [e-mail]
Time zone: CET: Central European Time  

This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication at 07:30 CET on May 29, 2020. (REGMAR)

About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our more than 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to - and benefits from - more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

https://news.cision.com/elekta/r/year-end-report-may-april-2019-20,c3122687

https://mb.cision.com/Main/35/3122687/1255584.pdf

https://news.cision.com/elekta/i/q4-2019-20-image-en,c2790237

(c) 2020 Cision. All rights reserved., source Press Releases - English